Telesis Bio Years Dividend Increased

What does Telesis Bio do? Codex DNA, Inc. develops genomic tools for biomedical and industrial applications, focusing on synthetic biology solutions to overcome bottlenecks in DNA and mRNA production. Its BioXp systems, including the BioXp 3250, serve as end-to-end automated workstations, while BioXp kits generate synthetic DNA and mRNA. The company offers 14 SARS-CoV-2 full-length genomes, RNA controls, and Vmax X2 cells as part of its product portfolio. BioXp systems are placed globally with approximately 200 units deployed. The firm targets researchers and biotech companies needing scalable DNA and mRNA synthesis, leveraging its automated workflow solutions. Products like BioXp kits and benchtop reagents complement the core systems, addressing limitations in current solutions. The company has launched eight BioXp kits and three benchtop reagent kits, supporting applications across biomedical and industrial sectors. Revenue streams come from selling BioXp systems, kits, and reagents directly to research institutions and biotechnology firms. The BioXp 3250 system, BioXp kits, and benchtop reagent kits are key products driving sales. Vmax X2 cells and SARS-CoV-2 related products also contribute to the company's revenue. Global deployment of 200 BioXp systems indicates strong market adoption among customers in the synthetic biology space. Telesis Bio is one of the most popular companies on Eulerpool.